SYNAGIS (MedImmune), SYNAGIS (Swedish Orphan Biovitrum AB (publ))
Remark
Therapeutic category:
6250
ATC code:
J06BD01
Product:
D02737<JP/US>
Efficacy
Antiviral, Anti-RS virus humanized antibody
Disease
Respiratory syncytial virus infection [DS:H00401]
Comment
Monoclonal antibody
Target
RSV F protein [KO:K19261]
Structure map
map07044
Antiviral agents
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J06 IMMUNE SERA AND IMMUNOGLOBULINS
J06B IMMUNOGLOBULINS
J06BD Antiviral monoclonal antibodies
J06BD01 Palivizumab
D02737 Palivizumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Respiratory Tract/Pulmonary Agents
Respiratory Tract Agents, Other
Immunomodulators
Palivizumab
D02737 Palivizumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
6 Agents against pathologic organisms and parasites
62 Chemotherapeutics
625 Antivirals
6250 Antivirals
D02737 Palivizumab (USAN/INN); Palivizumab (genetical recombination) (JAN)
Antimicrobials [BR:br08307]
Antivirals
Entry, fusion or uncoating inhibitor
RSV F protein
D02737 Palivizumab (USAN/INN) <JP/US>
Antimicrobials abbreviations [BR:br08327]
Antivirals
Entry, fusion or uncoating inhibitor
RSV F protein
D02737 Palivizumab (USAN/INN)
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D02737
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D02737